Related Experiment Video
Updated: Sep 21, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
IFNL4, ACE1, PKR, IFNG, MBL2 genetic polymorphisms and severe COVID-19: A protocol for systematic review and
1Guangzhou Medical University, Xinzao, Panyu District, Guangzhou City, Guangdong Province, People's Republic of China.
Background:
Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, the pathogenic process of SARS-Cov-2 is related to the angiotensin-2 converting enzyme (ACE-2) on host cells. The genetic polymorphisms among different populations may influence the progression of COVID-19. However, the effects of IFNL4, ACE1, PKR, IFNG, and MBL2 in severe COVID-19 have not been systematically assessed.
Methods:
We will include all relevant English and Chinese studies by searching the following electronic databases: PubMed, MEDLINE, Embase, Web of Science, Scopus, the Cochrane Library, and Google Scholar before March 31, 2022. Two researchers will independently screen and extract the literature. The methodological quality of the included studies will be evaluated by the Cochrane Handbook for Systematic Reviews of Interventions.
Result:
This systematic review and meta-analysis will summarize the association of IFNL4, ACE1, PKR, IFNG, MBL2 genetic polymorphisms, and severe COVID-19. The results will be submitted to a peer-reviewed journal once completed.
Conclusion:
The conclusion of our study will provide evidence for the early prevention of severe COVID-19.
Prospero Registration Number:
CRD42022301735.
Insights
This study examines genetic polymorphisms in IFNL4, ACE1, PKR, IFNG, and MBL2 and their association with severe COVID-19. Findings will aid in early prevention strategies for coronavirus disease 2019.
Area of Science:
- Genetics and Molecular Biology
- Infectious Diseases
- Immunology
Background:
- Severe COVID-19 pathogenesis involves SARS-CoV-2 interaction with host ACE-2.
- Genetic variations across populations may impact COVID-19 severity.
- The role of specific gene polymorphisms (IFNL4, ACE1, PKR, IFNG, MBL2) in severe COVID-19 remains unclear.
Purpose of the Study:
- To systematically review and meta-analyze the association between IFNL4, ACE1, PKR, IFNG, MBL2 genetic polymorphisms and severe COVID-19.
- To consolidate existing evidence on the genetic underpinnings of severe coronavirus disease 2019.
- To identify potential genetic markers influencing COVID-19 outcomes.
Main Methods:
- Comprehensive literature search of English and Chinese studies in major databases (PubMed, MEDLINE, Embase, Web of Science, Scopus, Cochrane Library, Google Scholar) up to March 31, 2022.
- Independent screening and data extraction by two researchers.
- Methodological quality assessment using the Cochrane Handbook for Systematic Reviews of Interventions.
Main Results:
- This systematic review and meta-analysis will synthesize data on the relationship between IFNL4, ACE1, PKR, IFNG, MBL2 genetic polymorphisms and severe COVID-19.
- Results will quantify the association, providing statistical evidence.
- Findings will be prepared for publication in a peer-reviewed journal.
Conclusions:
- The study will provide evidence regarding the influence of specific genetic polymorphisms on severe COVID-19.
- Results aim to contribute to the understanding of COVID-19 susceptibility and progression.
- Findings may inform early prevention strategies for severe coronavirus disease 2019.

